You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Bounding generalization risk for Deep Neural Networks

    SBC: Euler Scientific            Topic: NGA20A001

    Deep Neural Networks have become ubiquitous in the modern analysis of voluminous datasets with geometric symmetries. In the field of Particle Physics, experiments such as DUNE require the detection of particle signatures interacting within the detector, with analyses of over a billion 3D event images per channel each year; with typical setups containing over 150,000 different channels.  In an ...

    STTR Phase I 2020 Department of DefenseNational Geospatial-Intelligence Agency
  2. Human Performance Optimization: Ketone Esters for Optimization of Operator Performance in Hypoxia

    SBC: HVMN Inc.            Topic: SOCOM17C001

    In the setting of altitude-induced hypoxia, operator cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have sho ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  3. Human Performance Optimization

    SBC: REJUVENATE BIO INC            Topic: SOCOM17C001

    Special Operations Forces (SOF) are an integral aspect of the US military. SOF operators are among the most elite and highly qualified individuals in the U.S. military. As such, extraordinary physical and mental demands are placed upon them to excel in extreme environments for extended periods of time. This unrelenting cycle of combat deployments and intense pre-deployment training shortens the fu ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  4. Inhibiting Prolyl Hydroxylase to Mimic Natural Acclimatization to High Altitude to Improve Warfighter Performance at High Altitude

    SBC: Research Logistics Company            Topic: SOCOM17C001

    Acclimatization is the long-term adjustment that humans experience when exposed for weeks or months to high altitude. Acclimatization is important in this context because a warfighter who is acclimatized to high altitude is immune to high altitude illness, has superior work capacity, and has cognitive function approaching that found at sea level. In other words, the acclimatized warfighter is opti ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  5. System for Nighttime and Low-Light Face Recognition

    SBC: Systems & Technology Research LLC            Topic: SOCOM18A001

    Face recognition performance using deep learning has seen dramatic improvements in recent years. This improvement has been fueled in part by the curation of large labeled training datasets with millions of images of hundreds of thousands of subjects.This results in effective generalization for matching over pose, illumination, expression and age variation, however these datasets have traditionally ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  6. System for Nighttime and Low-Light Face Recognition

    SBC: MUKH Technologies LLC            Topic: SOCOM18A001

    Recognizing faces in low-light and nighttime conditions is a challenging problem due to the noisy and poor quality nature of the images.Thermal imaging is often used to obtain facial biometric in such conditions. Thermal face images, while having a strong signature at nighttime, are not typically maintained in biometric-enabled watch lists and so must be compared with visible-light face images to ...

    STTR Phase I 2018 Department of DefenseSpecial Operations Command
  7. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Virus-Like Particle Based pan-Marburgvirus Vaccine

    SBC: Luna Innovations Incorporated            Topic: CBD18A002

    Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government